Evofem BiosciencesEVFM +12.50% 9-Day RSI is 48.30 as of Jul. 06, 2026. The stock has 5 warning signs investors should review. Among 1,418 Biotechnology companies, Evofem Biosciences ranks better than 64.46% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Evofem Biosciences 9-Day RSI Related Terms
EVFM vs LYRA, CLSDQ, ATXI: 9-Day RSI Comparison
For the Biotechnology subindustry, Evofem Biosciences's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evofem Biosciences 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences (EVFM) has a 9-Day RSI of 48.30 as of Jul. 06, 2026. According to the industry distribution chart, Evofem Biosciences ranks #504 out of 1418 companies in the Biotechnology industry, placing it in the top 35.5%.
Is Evofem Biosciences' 9-Day RSI too high?
Evofem Biosciences' current 9-Day RSI is 48.30. The Biotechnology industry median 9-Day RSI is 53.71. Evofem Biosciences' value of 48.30 is 10.1% below this industry median. Based on the distribution chart, Evofem Biosciences ranks #504 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint.
How does Evofem Biosciences' 9-Day RSI compare to LYRA and CLSDQ?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #504 out of 1418 companies for 9-Day RSI. This puts Evofem Biosciences in the upper half of its industry. The industry median 9-Day RSI is 53.71. Evofem Biosciences' value of 48.30 is 10.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.71, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evofem Biosciences's current 9-Day RSI of 48.30 is 10.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evofem Biosciences's current 9-Day RSI is 48.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 10% below its estimated fair value. The current 9-Day RSI is 48.30 and 10.1% below the Biotechnology industry median of 53.71. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current 9-Day RSI is 48.30 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVFM has been successfully added to your